-
Mashup Score: 0Treating BCG-Refractory Disease and Explaining NMIBC Treatment Options to Patients | GU Oncology Now - 14 day(s) ago
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
Source: guoncologynow.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Machine Learning Model Outperforms Benchmarks in Predicting Renal Function | GU Oncology Now - 15 day(s) ago
Machine learning models can help with clinical decision making regarding renal function, according to new data.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⚙️ Presented at #SUO24, @JPersily and fellow researchers from NYU Langone Health have developed and externally validated a machine learning model to determine renal function after #nephrectomy, which was found to outperform previous benchmark datasets: https://t.co/XpSKx8GwTZ
-
-
Mashup Score: 9Advancing Neoadjuvant Therapies: Oncolytic Immunotherapy and Nivolumab in MIBC | GU Oncology Now - 16 day(s) ago
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 We spoke with @UrogerliMD on his research published in @NatureMedicine which focused on oncolytic #immunotherapy with #nivolumab for MIBC. 👉 This neoadjuvant regimen targets micrometastatic disease for non-muscle- and muscle-invasive bladder cancer: https://t.co/dQvMlwzAYO https://t.co/iAC1X1gS66
-
-
Mashup Score: 0Cretostimogene Grenadenorepvec Boosts Complete Response Rates, Lessens Progression of NMIBC | GU Oncology Now - 17 day(s) ago
Cretostimogene grenadenorepvec has demonstrated groundbreaking results for the treatment of high-risk Bacillus Calmette-Guérin-unresponsive NMIBC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
❗️ The immunotherapy drug cretostimogene grenadenorepvec has shown groundbreaking results for the treatment of HR BCG-unresponsive NMIBC based on BOND-003 data. 👉 The @cgoncology therapy received a Fast Track designation by the FDA in December 2023: https://t.co/oKLhZcfw1g
-
-
Mashup Score: 3
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Dr. Gordon Brown of @SummitHealthHQ leads a roundtable discussion featuring Drs. Tim Richardson of @WichitaUrology, Bryan Mehlhaff of @OUItweets, Chris Pieczonka, and @urogene. 📺 Watch the first part of their talk on the evolving landscape of NMIBC: https://t.co/GkSHQKC0Dn https://t.co/GIlAL1kIHg
-
-
Mashup Score: 0Real-World Results of Olaparib for HRRm+ Castration-Resistant Prostate Cancer | GU Oncology Now - 20 day(s) ago
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
Source: guoncologynow.comCategories: General Medicine News, Oncologists1Tweet-
🧪 A recent analysis provides data on treatment patterns for patients with HRRm #mCRPC treated with #olaparib monotherapy. 👉 Learn how olaparib affects patients with germline or somatic mutations in key HRR genes, including BRCA1, BRCA2, and others: https://t.co/aSBjJQKBO3
-
-
Mashup Score: 19Navigating Treatment Complexities in First- and Second-Line Therapies for mRCC | GU Oncology Now - 21 day(s) ago
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Watch @ReginaBarCar discuss her paper on updates in the field of mRCC. 👉 Co-authors @DrChoueiri, @ReneeSaliby, @tompowles1, @ERPlimackMD, and @eddy_saad contributed to the review, which includes a guide on 1st and 2nd-line treatments for mRCC: https://t.co/0D73WGi0AU https://t.co/03nwCbVnwA
-
-
Mashup Score: 2IMvigor011 Exploratory Analysis Reveals OS, DFS Rates of ctDNA-Negative Patients With MIBC | GU Oncology Now - 21 day(s) ago
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA-positive post-cystectomy using Signatera.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
❇️ At #SUO24, an exploratory analysis of the phase III IMvigor011 trial’s surveillance cohort has provided new data on the DFS and OS rates of patients with HR #MIBC who have continual ctDNA-negative biomarker status after undergoing cystectomy: https://t.co/vAFWgBiIck
-
-
Mashup Score: 0Locoregional Recurrence Risk Score Effectively Stratifies Patients With nmUC | GU Oncology Now - 22 day(s) ago
A recent study presented at the 25th Annual Meeting of the Society of Urologic Oncology sought to develop and validate a tool to determine factors associated with LR post-RC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
👉 A new study from #SUO24 has developed a tool to determine factors associated with locoregional recurrence post-radical cystectomy for urothelial carcinoma. 📋 LR can result in poor prognosis, and reported cases vary widely in medical literature: https://t.co/ZHmTBHRfEf
-
-
Mashup Score: 1CG Oncology to Showcase Phase 3 Results and Ongoing Trials on Cretostimogene Grenadenorepvec at SUO | GU Oncology Now - 23 day(s) ago
Several posters and a late-breaking abstract will highlight data on cretostimogene grenadenorepvec for bladder cancer.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
❗️ A late-breaking abstract detailing results from the BOND-003 trial will be presented at #SUO24 tomorrow by @MarkTysonMD for @cgoncology. 🔬 Cretostimogene grenadenorepvec is under evaluation for its ability to target HR #bladdercancer: https://t.co/54l9PdrBIE
-
📺 In the second part of our NMIBC roundtable, the panelists address the increasing availability of intravesical and systemic therapies, the importance of accurate risk stratification, and the role of education for both health care providers and patients: https://t.co/chU75Qvzm6